India to Conduct 5% Global Clinical Trials by 2012

Delhi, Iceland, February 05, 2009 --(PR.com)-- India is fast becoming one of the biggest hubs for conducting global clinical trials. In 2007, the country conducted around 220 clinical trials, making up for less than 2% of the global clinical trials But according to “Booming Clinical Trials Market in India”, a new research report by RNCOS, a number of factors such as low cost, large patient pool, easy recruitment, strong government support and strengthening of its intellectual property environment will enable India to conduct nearly 5% of the global clinical trials by 2012.

As per the report, India scores well above many other destinations in almost every factor analyzed. For instance, India provides one of the largest patient pools for both infectious and chronic diseases. Moreover, the country has 40 million diabetics, representing the largest in any country. Similarly, India also has one of the highest numbers of patients for other chronic diseases such as cardiovascular, neurological disorders, respiratory disorders and obesity. Apart from chronic disorders, the country also provides one of the largest numbers of patients for such infectious diseases as HIV, malaria and tuberculosis.

The findings of the report suggest that not only does India provide a large patient pool, the recruitment of these patients is also among the fastest in the world. As most of the healthcare costs in India are paid “out of pocket”, a large patient population continues to have unmet medical needs. As a result, they readily volunteer to participate in clinical trials to get free treatment.

“Booming Clinical Trials Market in India” gives an extensive and objective analysis on the Indian clinical trials market. It investigates the advantages and disadvantages India has over other countries to become a global clinical trials hub. The report exhaustively evaluates and compares the key factors that drug companies and CROs look before outsourcing clinical trials to a country. These include factors such as patient pool, regulatory environment, cost, infrastructure, human resources and past performance in conducting clinical trials.

Thus, the report serves as a useful guide for drug manufacturers, CROs, consultants and investors who are planning to enter the Indian clinical trials market.

For Free Sample of this report visit: http://www.rncos.com/Report/IM564.htm

About RNCOS:

RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.

###